Pharmacogenomics of osteoporosis

Current Pharmacogenomics

Volumn 5, Issue 3, 2007, Pages 214-227

  Hernández, José L ^a   Riancho, José A ^a  

^a UNIVERSITY OF CANTABRIA   (Spain)

Author keywords

Antiosteoporotic Drugs; Bone mineral density; Bone Remodeling; Estrogens; Hormone Replacement Therapy; Vitamin D

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; ANABOLIC AGENT; ANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCITRIOL; CALCIUM; CLODRONIC ACID; ESTROGEN; ESTROGEN RECEPTOR; ETIDRONIC ACID; IBANDRONIC ACID; PAMIDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; TIBOLONE; VITAMIN D; VITAMIN D RECEPTOR; ZOLEDRONIC ACID;

BONE DENSITY; BONE FRAGILITY; BONE MASS; BONE REMODELING; BONE TURNOVER; CALCIUM INTAKE; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG CLASSIFICATION; DRUG MECHANISM; DRUG RESPONSE; DRUG USE; ENVIRONMENTAL FACTOR; ESTROGEN ACTIVITY; ESTROGEN METABOLISM; FRACTURE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HEREDITY; HORMONE SUBSTITUTION; HUMAN; MONOTHERAPY; OSTEOLYSIS; OSTEOPOROSIS; PHARMACOGENOMICS; POSTMENOPAUSE; PREVALENCE; REPRODUCIBILITY; REVIEW; RISK FACTOR; RISK REDUCTION;

EID: 34648819541     PISSN: 15701603     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016007781669196     Document Type: Review

References (114)

1. Anonimous. (1994) NIH Consensus conference. Optimal calcium intake. NIH consensus development panel on optimal calcium intake. JAMA 272, 1942-1948.
2. Arko, B.; Prezelj, J.; Komel, R.; Kocijancic, A. and Marc, J. (2002) No major effect of estrogen receptor beta gene RsaI polymorphism on bone mineral density and response to alendronate therapy in post-menopausal osteoporosis. J. Steroid Biochem. Mol. Biol. 81, 147-152.
3. Baldock, P. A. and Eisman, J. A. (2004) Genetic determinants of bone mass. Curr. Opin. Rheumatol. 16, 450-456.
4. Barrett-Connor, E.; Mosca, L.; Collins, P.; Geiger, M. J.; Grady, D.; Kornitzer, M.; McNabb, M. A. and Wenger, N. K. (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N. Engl. J. Med. 355, 125-137.
5. Brodowska, A. (2003) [The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes]. Ann. Acad. Med. Stetin. 49, 111-130.
6. Brown, M. A.; Haughton, M. A.; Grant, S. F.; Gunnell, A. S.; Henderson, N. K. and Eisman, J. A. (2001) Genetic control of bone density and turnover: role of the collagen 1 alpha 1, estrogen receptor, and vitamin D receptor genes. J. Bone Miner. Res. 16, 758-764.
7. Cauley, J. A.; Robbins, J.; Chen, Z.; Cummings, S. R.; Jackson, R. D.; Lacroix, A. Z.; LeBoff, M.; Lewis, C. E.; McGowan, J.; Neuner, J.; Pettinger, M.; Stefanick, M. L.; Wactawski-Wende, J. and Watts, N. B. (2003) Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 290, 1729-1738.
8. Coombs, N. J.; Taylor, W.; Wilcken, N. and Boyages, J. (2005) Hormone replacement therapy and breast cancer: estimate of risk. BMJ 331, 347-349.
9. Corral-Gudino, L.; Pino-Montes, J.; Garcia-Aparicio, J.; Corral, E.; Montilla, C. A. and Gonzalez-Sarmiento, R. (2006) -511 C/T IL1B gene polymorphism is associated to resistance to bisphosphonates treatment in Paget disease of bone. Bone 38, 589-594.
10. Coxon, F. P.; Thompson, K. and Rogers, M. J. (2006) Recent advances in understanding the mechanism of action of bisphosphonates. Curr. Opin. Pharmacol. 6, 307-312.
11. Cranney, A.; Guyatt, G.; Griffith, L.; Wells, G.; Tugwell, P. and Rosen, C. (2002) Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr. Rev. 23, 570-578.
12. Cusack, S. and Cashman, K. D. (2003) Impact of genetic variation on metabolic response of bone to diet. Proc. Nutr. Soc. 62, 901-912.
13. Dawson-Hughes, B.; Harris, S. S. and Finneran, S. (1995) Calcium absorption on high and low calcium intakes in relation to vitamin D receptor genotype. J. Clin. Endocrinol. Metab. 80, 3657-3661.
14. Dawson-Hughes, B.; Heaney, R. P.; Holick, M. F.; Lips, P.; Meunier, P. J. and Vieth, R. (2005) Estimates of optimal vitamin D status. Osteoporos. Int. 16, 713-716.
15. Deng, H. W.; Li, J.; Li, J. L.; Johnson, M.; Gong, G.; Davis, K. M. and Recker, R. R. (1998) Change of bone mass in postmenopausal Caucasian women with and without hormone replacement therapy is associated with vitamin D receptor and estrogen receptor genotypes. Hum. Genet. 103, 576-585.
16. Dennison, E.; Cole, Z. and Cooper, C. (2005) Diagnosis and epidemiology of osteoporosis. Curr. Opin. Rheumatol. 17, 456-461.
17. Ettinger, B.; Black, D. M.; Mitlak, B. H.; Knickerbocker, R. K.; Nickelsen, T. and Genant, H. K. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA 282, 637-645.
18. Ferrari, S.; Rizzoli, R.; Marten, D.; Slosman, D. and Bonjour, J. P. (1998) Vitamin D receptor gene start codon polymorphisms (Fokl) and bone mineral density: interaction with age, dietary calcium, and 3i-end region polymorphisms. J. Bone Miner. Res. 13, 925-930.
19. Ferrari, S. L.; Karasik, D.; Liu, J.; Karamohamed, S.; Herbert, A. G.; Cupples, L. A. and Kiel, D. P. (2004) Interactions of interleukin-6 promoter polymorphisms with dietary and lifestyle factors and their association with bone mass in men and women from the Framingham Osteoporosis Study. J. Bone Miner. Res. 19, 552-559.
20. Gabriel, S. E.; Tosteson, A. N.; Leibson, C. L.; Crowson, C. S.; Pond, G. R.; Hammond, C. S. and Melton, L. J.; III (2002) Direct medical costs attributable to osteoporotic fractures. Osteoporos. Int. 13, 323-330.
21. Gilad, L. A.; Bresler, T.; Gnainsky, J.; Smirnoff, P. and Schwartz, B. (2005) Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells. J Endocrinol. 185, 577-592.
22. Gillespie, W. J.; Avenell, A.; Henry, D. A.; O'Connell, D. L. and Robertson, J. (2001) Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst. Rev. CD000227.
23. Graafmans, W. C.; Lips, P.; Ooms, M. E.; van Leeuwen, J. P.; Pols, H. A. and Uitterlinden, A. G. (1997) The effect of vitamin D supplementation on the bone mineral density of the femoral neck is associated with vitamin D receptor genotype. J. Bone Miner. Res. 12, 1241-1245.
24. Grant, A. M.; Avenell, A.; Campbell, M. K.; McDonald, A. M.; MacLennan, G. S.; McPherson, G. C.; Anderson, F. H.; Cooper, C.; Francis, R. M.; Donaldson, C.; Gillespie, W. J.; Robinson, C. M.; Torgerson, D. J. and Wallace, W. A. (2005) Oral vitamin D3 and calcium for secondary prevention of low-trauma fractures in elderly people (Randomised Evaluation of Calcium Or vitamin D, RECORD): a randomised placebo-controlted trial. Lancet 365, 1621-1628.
25. Gruber, C. J.; Tschugguel, W.; Schneeberger, C. and Huber, J. C. (2002) Mechanisms of disease: production and actions of estrogens. N. Engl. J. Med. 346, 340-352.
26. Han, K. O.; Choi, J. T.; Moon, I. G.; Jeong, M. S.; Yim, C. H.; Chung, H. Y.; Jang, H. C.; Yoon, H. K. and Han, I. K. (2002) Nonassociation of interleukin-1 receptor antagonist genotypes with bone mineral density, bone turnover status, and estrogen responsiveness in Korean postmenopausal women. Bone 31, 612-615.
27. Haussler, M. R.; Haussler, C. A.; Jurutka, P. W.; Thompson, P. D.; Hsieh, J. C.; Remus, L. S.; Selznick, S. H. and Whitfield, G. K. (1997) The vitamin D hormone and its nuclear receptor: molecular actions and disease states. J. Endocrinol. 154(Suppl.), S57-S73.
28. Heaney, R. P. (1986) "Calcium, bone health, and osteoporosis," In Bone and Mineral Res. 4 edition, Peck, W. A. Ed.; Elsevier: Amsterdam, pp. 255-300.
29. Heaney, R. P. and Weaver, C. M. (2003) Calcium and vitamin D. Endocrinol. Metab. Clin. North Am. 32, 181-viii.
30. Heikkinen, A. M.; Niskanen, L. K.; Salmi, J. A.; Koulu, M.; Pesonen, U.; Uusitupa, M. I.; Komulainen, M. H.; Tuppurainen, M. T.; Kroger, H.; Jurvelin, J. and Saarikoski, S. (2004) Leucine7 to proline7 polymorphism in prepro-NPY gene and femoral neck bone mineral density in postmenopausal women. Bone 35, 589-594.
31. Heilberg, I. P.; Hernandez, E.; Alonzo, E.; Valera, R.; Ferreira, L. G.; Gomes, S. A.; Bellorin-Font, E. and Weisinger, J. R. (2005) Estrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis. Ren. Fail. 27, 155-161.
32. Herrington, D. M.; Howard, T. D.; Brosnihan, K. B.; McDonnell, D. P.; Li, X.; Hawkins, G. A.; Reboussin, D. M.; Xu, J.; Zheng, S. L.; Meyers, D. A. and Bleecker, E. R. (2002a) Common estrogen receptor polymorphism augments effects of hormone replacement therapy on E-selectin but not C-reactive protein. Circulation 105, 1879-1882.
33. Herrington, D. M.; Howard, T. D.; Hawkins, G. A.; Reboussin, D. M.; Xu, J.; Zheng, S. L.; Brosnihan, K. B.; Meyers, D. A. and Bleecker, E. R. (2002b) Estrogen-receptor polymorphisms and effects of estrogen replacement on high-density lipoprotein cholesterol in women with coronary disease. N. Engl. J. Med. 346, 967-974.
34. Hochberg, M. (2000) Preventing fractures in postmenopausal women with osteoporosis. A review of recent controlled trials of antiresorptive agents. Drugs Aging 17, 317-330.
35. Hofbauer, L. C. and Heufelder, A. E. (2001) Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. J. Mol. Med. 79, 243-253.
36. Ioannidis, J. P.; Ralston, S. H.; Bennett, S. T.; Brandi, M. L.; Grinberg, D.; Karassa, F. B.; Langdahl, B.; van Meurs, J. B.; Mosekilde, L.; Scollen, S., Albagha, O. M.; Bustamante, M.; Carey. A. H.; Dunning, A. M.; Enjuanes, A.; van Leeuwen. J. P.; Mavilia, C.; Masi, L.; McGuigan, F. E.; Nogues, X.; Pols, H. A.; Reid, D. M.; Schuit, S. C.; Sherlock, R. E.; Uitterlinden, A. G. and Genomos Study. (2004) Differential genetics effects of ESR1 gene polymorphisms on osteoporosis outcomes. JAMA 292, 2105-2114.
37. Jackson, R. D.; Lacroix, A. Z.; Gass, M.; Wallace, R. B.; Robbins, J., Lewis, C. E.; Bassford, T.; Beresford, S. A.; Black, H. R.; Blanchette, P.; Bonds, D. E.; Brunner, R. L.; Brzyski, R. G.; Caan, B.; Cauley, J. A.; Chlebowski, R. T.; Cummings, S. R.; Granek, I.; Hays, J.; Heiss, G.; Hendrix, S. L.; Howard, B. V.; Hsia, J.; Hubbell, F. A.; Johnson, K. C.; Judd, H.; Kotchen, J. M.; Koller, L. H.; Langer, R. D.; Lasser, N. L.; Limacher, M. C.; Ludlam, S.; Manson, J. E.; Margolis, K. L.; McGowan, J.; Ockene, J. K.; O'Sullivan, M. J.; Phillips, L.; Prentice, R. L.; Sarto, G. E.; Stefanick, M. L.; Van Horn, L.; Wactawski-Wende, J.; Whitlock, E.; Anderson, G. L., Assaf, A. R. and Barad, D. (2006) Calcium plus vitamin D supplementation and the risk of fractures. N. Engl. J. Med. 354, 669-683.
38. Johnell, O. and Kanis, J. A. (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos. Int. 17, 1726-1733.
39. Kamat, A.; Hinshelwood, M. M.; Murry, B. A. and Mendelson, C. R. (2002) Mechanisms in tissue-specific regulation of estrogen biosynthesis in humans. Trends Endocrinol. Metab. 13, 122-128.
40. Kanis, J. A.; Johansson, H.; Oden, A.; De Laet, C.; Johnell, O.; Eisman, J. A.; Mc, C. E.; Mellstrom, D.; Pols, H.; Reeve, J.; Silman, A. and Tenenhouse, A. (2005) A meta-analysis of milk intake and fracture risk: low utility for case finding. Osteoporos. Int. 16, 799-804.
41. Kendler, D. L. (2006) Strontium ranelate - data on vertebral and nonvertebral fracture efficacy and safety: mechanism of action. Curr. Osteoporos. Rep. 4, 34-39.
42. Kim, J. G.; Choi, Y. M.; Moon, S. Y. and Leé, J. Y. (2003) Association of the calcitonin gene (CA) polymorphism with bone mass and bone responsiveness to hormone therapy in postmenopausal Korean women. Menopause 10, 544-549.
43. Koay, M. A.; Woon, P. Y.; Zhang, Y.; Miles, L. J.; Duncan, E. L.; Ralston, S. H.; Compston, J. E.; Cooper, C.; Keen, R.; Langdahl, B. L.; MacLelland, A.; O'Riordan, J.; Pols, H. A.; Reid, D. M.; Uitterlinden, A. G.; Wass, J. A. and Brown, M. A. (2004) Influence of LRP5 polymorphisms on normal variation in BMD. J. Bone Miner. Res. 19, 1619-1627.
44. Kobayashi, N.; Fujino, T.; Shirogane, T.; Furuta, I.; Kobamatsu, Y.; Yaegashi, M.; Sakuragi, N. and Fujimoto, S. (2002) Estrogen receptor alpha polymorphism as a genetic marker for bone loss, vertebral fractures and susceptibility to estrogen. Maturitas 41, 193-201.
45. Kobayashi, S.; Inoue, S.; Hosoi, T.; Ouchi, Y.; Shiraki, M. and Orimo, H. (1996) Association of bone mineral density with polymorphism of the estrogen receptor gene. J. Bone Miner. Res. 11, 306-311.
46. Koehler, K. F.; Helguero, L. A.; Haldosén, L. A.; Warner, M. and Gustafsson, J. A. (2005) Reflections on the discovery and significance of estrogen receptor 8. Endocr. Rev. 26, 465-478.
47. Krane, S. M. (2005) Identifying genes that regulate bone remodeling as potential therapeutic targets. J. Exp. Med. 201, 841-843.
48. Kurabayashi, T.; Matsushita, H.; Tomita, M.; Kato, N.; Kikuchi, M.; Nagata, H.; Honda, A.; Yahata, T. and Tanaka, K. (2004) Association of vitamin D and estrogen receptor gene polymorphism with the effects of longterm hormone replacement therapy on bone mineral density. J. Bone Miner. Metab. 22, 241-247.
49. Kurabayashi, T.; Tomita, M.; Matsushita, H.; Yahata, T.; Honda, A.; Takakuwa, K. and Tanaka, K. (1999) Association of vitamin D and estrogen receptor gene polymorphism with the effect of hormone replacement therapy on bone mineral density in Japanese women. Am. J. Obstet. Gynecol. 180, 1115-1120.
50. Leskela, H. V.; Olkku, A.; Lehtonen, S.; Mahonen, A.; Koivunen, J.; Turpeinen, M.; Uusitalo, J.; Pelkonen, O.; Kangas, L.; Selander, K. and Lehenkari, P. (2006) Estrogen receptor alpha genotype confers interindividual variability of response to estrogen and testosterone in mesenchymal-stem-cell-derived osteoblasts. Bone 39, 1026-1034.
51. Lips, P. (2006) Vitamin D physiology. Prog. Biophys. Mol. Biol. 92, 4-8.
52. Liu, Y. J.; Shen, H.; Xiao, P.; Xiong, D. H.; Li, L. H.; Recker, R. R. and Deng, H. W. (2006) Molecular genetic studies of gene identification for osteoporosis: a 2004 update. J. Bone Miner. Res. 21, 1511-1535.
53. Liu, Y. Z.; Liu, Y. J.; Recker, R. R. and Deng, H. W. (2003) Molecular studies of identification of genes for osteoporosis: the 2002 update. J. Endocrinol. 177, 147-196.
54. Lorenzo, J. (2003) A new hypothesis for how se steroid hormones regulate bone mass. J. Clin. Invest. 111, 1641-1643.
55. Marc, J.; Prezelj, J.; Komel, R. and Kocijancic, A. (1999) VDR genotype and response to etidronate therapy in late postmenopausal women. Osteoporos. Int. 10, 303-306.
56. Matsuyama, T.; Ishii, S.; Tokita, A.; Yabuta, K.; Yamamori, S.; Morrison, N. A. and Eisman, J. A. (1995) Vitamin D receptor genotypes and bone mineral density. Lancet 345, 1238-1239.
57. Michaelsson, K.; Melhus, H.; Ferm, H.; Ahlbom, A. and Pedersen, N. L. (2005) Genetic liability to fractures in the elderly. Arch. Intern. Med. 165, 1825-1830.
58. Monkkonen, H.; Auriola, S.; Lehenkari, P.; Kellinsalmi, M.; Hassinen, I. E.; Vepsalainen, J. and Monkkonen, J. (2006) A new endogenous ATP analog (Apppl) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br. J. Pharmacol. 147, 437-445.
59. Morrison, N. A,; George, P. M.; Vaughan, T.; Tilyard, M. W.; Frampton, C. M. and Gilchrist, N. L. (2005) Vitamin D receptor genotypes influence the success of calcitriol therapy for recurrent vertebral fracture in osteoporosis. Pharmacogenet. Genomics 15, 127-135.
60. Morrison, N. A.; Qi, J. C.; Tokita, A.; Kelly, P. A.; Crofts, L.; Nguyen, T. V.; Sambrook, P. N. and Eisman, J. A. (1994) Prediction of bone density from vitamin D receptor alleles. Nature 367, 284-287.
61. Nguyen, T. V. (2005) Pharmacogenetics of anti-resorptive therapy efficacy: a Bayesian interpretation. Osteoporos. Int. 16, 857-860.
62. NIH consensus development panel on osteoporosis prevention diagnosis and therapy. (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285, 785-795.
63. North American Menopause Society. (2006) The role of calcium in peri-and postmenopausal women; 2006 position statement of The North American Menopause Society. Menopause 13, 862-877.
64. Ongphiphadhanakul, B.; Chanprasertyothin, S.; Payatikul, P.; Tung, S. S.; Piaseu, N.; Chailurkit, L.; Chansirikarn, S.; Puavilai, G. and Rajatanavin, R. (2000) Oestrogen-receptor-alpha gene polymorphism affects response in bone mineral density to oestrogen in post-menopausal women. Clin. Endocrinol. (Oxford) 52, 581-585.
65. Ongphiphadhanakul, B.; Chanprasertyothin, S.; Payattikul, P.; Saetung, S.; Piaseu, N.; Chailurkit, L.; Chansirikam, S.; Puavilai, G. and Rajatanavin, R. (2001) Association ofa T262C transition in exon 1 of estrogen-receptor-alpha gene with skeletal responsiveness to estrogen in post-menopausal women. J. Endocrinol. Invest. 24, 749-755.
66. Onland-Moret, N. C.; van Gils, C. H.; Roest, M.; Grobbee, D. E. and Peeters, P. H. (2005) The estrogen receptor alpha gene and breast cancer risk (The Netherlands). Cancer Causes Control 16, 1195-1202.
67. Ouyang, P.; Michos, E. D. and Karas, R. H. (2006) Hormone replacement therapy and the cardiovascular system lessons learned and unanswered questions. J. Am. Coll. Cardial. 47, 1741-1753.
68. Owada, M.; Suzuki, K.; Honda, T.; Yamada, H.; Tsukikawa, S.; Hoshi, K. and Sato, A. (1996) [Effect of vitamin D receptor gene polymorphism on vitamin D therapy for postmenopausal bone loss]. Nippon Sanka Fujinka Gakkai Zasshi 48, 799-805.
69. Painter, S. E.; Kleerekoper, M. and Camacho, P. M. (2006) Secondary osteoporosis: a review of the recent evidence. Endocr. Pract. 12, 436-445.
70. Palomba, S.; Numis, F. G.; Mossetti, G.; Rendina, D.; Vuotto, P.; Russo, T.; Zullo, F.; Nappi, C. and Nunziata, V. (2003a) Effectiveness of alendronate treatment in postmenopausal women with osteoporosis: relationship with Bsml vitamin D receptor genotypes. Clin. Endocrinol. (Oxf) 58, 365-371.
71. Palomba, S.; Numis, F. G.; Mossetti, G.; Rendina, D.; Vuotto, P.; Russo, T.; Zullo, F.; Nappi, C. and Nunziata, V. (2003b) Raloxifene administration in post-menopausal women with osteoporosis: effect of different BsmI vitamin D receptor genotypes. Hum. Reprod. 18, 192-198.
72. Palomba, S.; Orio, F., Jr.; Russo, T.; Falbo, A.; Tolino, A.; Manguso, F.; Nunziata, V.; Mastrantonio, P.; Lombardi, G. and Zao, F. (2005) BsmI vitamin D receptor genotypes influence the efficacy of antiresorptive treatments in postmenopausal osteoporotic women. A 1-year multicenter, randomized and controlled trial. Osteoporos. Int. 16, 943-952.
73. Papadimitropoulos, E.; Wells, G.; Shea, B.; Gillespie, W.; Weaver, B.; Zytaruk, N.; Cranney, A.; Adachi, J.; Tugwell, P.; Josse, R.; Greenwood, C. and Guyatt, G. (2002) Meta-analyses of therapies for postmenopausal osteoporosis. VIII: Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr. Rev. 23, 560-569.
74. Parfitt, A. M. (2000) The mechanism of coupling, Bone 26, 319-323.
75. Peacock, M.; Turner, C. H.; Econs, M. J. and Foroud, T. (2002) Genetics of osteoporosis. Endocr. Rev. 23, 303-326.
76. Prince, R. L.; Devine, A.; Dhaliwal, S. S. and Dick, I. M. (2006) Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women. Arch. Intern. Med. 166, 869-875.
77. Qureshi, A. M.; Herd, R. J.; Blake, G. M.; Fogelman, I. and Ralstron, S. H. (2002) COLIA1 Sp1 polymorphism predicts response of femoral neck bone density to cyclical etidronate therapy. Calcif. Tissue Int. 70, 158-163.
78. Ralston, S. H. (2002) Genetic control of susceptibility to osteoporosis. J. Clin. Endocrinol. Metab. 87, 2460-2466.
79. Ralston, S. H. and de Crombrugghe, B. (2006a) Genetic regulation of bone mass and susceptibility to osteoporosis. Genes Dev. 20, 2492-2506.
80. Ralston, S. H.; Uitterlinden, A. G.; Brandi, M. L.; Balcells, S.; Langdahl, B. L.; Lips, P.; Lorenc, R.; Obermayer-Pietsch, B.; Scollen, S.; Bustamante, M.; Hosted, L. B.; Carey, A. H.; Diez-Perez, A.; Dunning, A. M.; Falchetti, A.; Karczmarewicz, F.; Kruk, M.; van Leeuwen, J. P.; van Meurs, J. B.; Mangion, J.; McGuigan, F. E.; Mellibovsky, L.; Del Monte, F.; Pols, H. A.; Reeve, J.; Reid, D. M.; Renner, W.; Rivadeneira, F.; van Schoor, N. M.; Sherlock, R. E. and Ioannidis, J. P. (2006b) Large-scale evidence for the effect of the COLIA1 Sp1 polymorphism on osteoporosis outcomes: the GENOMOS study. PLoSMed. 3, e90.
81. Rapuri, P. B.; Gallagher, J. C.; Knezetic, J. A. and Haynatzka, V. (2006) Estrogen receptor alpha gene polymorphisms are associated with changes in bone remodeling markers and treatment response to estrogen. Maturitas 53, 371-379.
82. Reid, I. R.; Mason, B.; Home, A.; Ames, R.; Reid, H. E.; Bava, U.; Bolland, M. J. and Gamble, G. D. (2006) Randomized controlled trial of calcium in healthy older women. Am. J. Med. 119, 777-785.
83. Retornaz, F.; Paris, F.; Lumbroso, S,; Audran, F.; Tigoulet, F.; Michelon, C.; Jeandel, C.; Sultan, C. and Blain, H. (2006) Association between androgen receptor gene polymorphism and bone density in older women using hormone replacement therapy. Maturitas 55(4), 325-333.
84. Riancho, J. A.; Zarrabeitia, M. T.; Valero, C.; Sanudo, C.; Hernandez, J. L.; Amado, J. A.; Zarrabeitia, A. and Gonzalez-Macias, J. (2005) Aromatase gene and osteoporosis: relationship of ten polymorphic loci with bone mineral density. Bone 36, 917-925.
85. Riancho, J. A.; Zarrabeitia, M. T.; Valero, C.; Sanudo, C.; Mijares, V. and Gonzalez-Macias, J. (2006) A gene-to-gene interaction between aromatase and estrogen receptors influences bone mineral density. Eur. J. Endocrinol. 155, 53-59.
86. Riggs, B. L. (2000) The mechanisms of estrogen regulation of bone resorption. J. Clin. Invest. 106, 1203-1204.
87. Riggs, B. L. and Melton, L. J. III. (1986) Involutional osteoporosis. N. Engl. J. Med. 314, 1676-1686.
88. Riggs, B. L. and Parfitt, A. M. (2005) Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J. Bone Miner. Res. 20, 177-184.
89. Rubin, M. R. and Bilezikian, J. P. (2003) New anabolic therapies in osteoporosis. Endocrinol. Metab. Clin. North Am. 32, 285-307.
90. Russell, R. G.; Croucher, P. I. and Rogers, M. J. (1999) Bisphosphonates: pharmacology, mechanisms of action and clinical uses. Osteoporos. Int. 9(Suppl 2), S66-S80.
91. Salmen, T.; Heikkinen, A. M.; Mahonen, A.; Kroger, H.; Komulainen, M.; Pallonen, H.; Saarikoski, S.; Honkanen, R. and Maenpaa, P. H. (2003) Relation of androgen receptor gene polymorphism to bone mineral density and fracture risk in early postmenopausal women during a 5-year randomized hormone replacement therapy trial. J. Bone Miner. Res. 18, 319-324.
92. Sambrook, P. and Cooper, C. (2006) Osteoporosis. Lancet 367, 2010-2018.
93. Shea, B.; Wells, G.; Cranney, A.; Zytaruk, N.; Robinson, V.; Griffith, L.; Ortiz, Z.; Peterson, J.; Adachi, J.; Tugwell, P. and Guyatt, G. (2002) Meta-analyses of therapies for postmenopausal osteoporosis. VII Meta-analysis of calcium supplementation for the prevention of postmenopausal osteoporosis. Endocr. Rev. 23, 552-559.
94. Silvestri, S.; Carbonell, S. S.; Christiansen, C. and Brandi, M. (2006a) Polymorphism in farnesyl pyrophosphate-synthase (FDPS) gene and relation with bone mineral density and response to aminobisfosfonate treatment. Calcif Tissue Int. 78(suppl 1), S121.
95. Silvestri, S.; Thomsen, A. B.; Gozzini, A.; Bagger, Y.; Christiansen, C. and Brandi, M. L. (2006b) Estrogen receptor alpha and beta polymorphisms: is there an association with bone mineral density, plasma lipids, and response to postmenopausal hormone therapy? Menopause 13, 451-461.
96. Siris, E. S. (2006) Patients with hip fracture: what can be improved? Bone 38, S8-S12.
97. Stewart, T. L.; Jin, H.; McGuigan, F. E.; Albagha, O. M.; Garcia-Giralt, N.; Bassiti, A.; Grinberg, D.; Balcells, S.; Reid, D. M. and Ralston, S. H. (2006) Haplotypes defined by promoter and intron 1 polymerphisms of the COLIA1 gene regulate bone mineral density in women. J. Clin. Endocrinol. Metab. 91, 3575-3583.
98. Syed, F. S. and Khosla, S. (2005) Mechanisms of sex steroid effects on bone. Biochem. Biophys. Res. Commun. 328, 688-696.
99. Tashjian, A. H. Jr. and Gagel, R. F. (2006) Teriparatide [human PTH(1-34)]: 2.5 years of experience on the use and safety of the drug for the treatment of osteoporosis. J. Bone Miner. Res. 21, 354-365.
100. Thacher, T. D.; Fischer, P. R.; Pettifor, J. M.; Lawson, J. O.; Isichei, C. O.; Reading, J. C. and Chan, G. M. (1999) A comparison of calcium, vitamin D, or both for nutritional rickets in Nigerian children. N. Engl. J. Med. 341, 563-568.
101. Tofteng, C. L.; Abrahamsen, B.; Jensen, J. E.; Petersen, S.; Teilmann, J.; Kindmark, A.; Vestergaard, P.; Gram, J.; Langdahl, B. L. and Mosekilde, L. (2004a) Two single nucleotide polymorphisms in the CYP17 and COMT Genes-relation to bone mass and longitudinal bone changes in postmenopausal women with or without hormone replacement therapy. The Danish Osteoporosis Prevention Study. Calcif Tissue Int. 75, 123-132.
102. Tofteng, C. L.; Jensen, J. E.; Abrahamsen, B.; Odum, L. and Brot, C. (2002) Two polymorphisms in the vitamin D receptor gene - association with bone mass and 5-year change in bone mass with or without hormone-replacement therapy in postmenopausal women: the Danish Osteoporosis Prevention Study. J. Bone Miner. Res. 17, 1535-1544.
103. Tofteng, C. L.; Kindmark, A.; Brandstrom, H.; Abrahamsen, B.; Petersen, S.; Stiger, F.; Stilgren, L. S.; Jensen, J. E.; Vestergaard, P.; Langdahl, B. L. and Mosekilde, L. (2004b) Polymorphisms in the CYP19 and AR genes-relation to bone mass and longitudinal bone changes in postmenopausal women with or without hormone replacement therapy: The Danish Osteoporosis Prevention Study. Calcif Tissue Int. 74, 25-34.
104. Tortes, A.; Garcia, S.; Gomez, A.; Gonzalez, A.; Barrios, Y.; Concepcion, M. T.; Hernandez, D.; Garcia, J. J.; Checa, M. D.; Lorenzo, V. and Salido, E. (2004) Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation. Kidney Int. 65, 705-712.
105. Uitterlinden, A. G.; Fang, Y.; van Meurs, J. B.; Pols, H. A. and van Leeuwen, J. P. (2004) Genetics and biology of vitamin D receptor polymorphisms. Gene 338, 143-156.
106. Uitterlinden, A. G.; Ralston, S. H.; Brandi, M. L.; Carey, A. H.; Grinberg, D.; Langdahl, B. L.; Lips, P.; Lorene, R.; Obermayer-Pietsch, B.; Reeve, J.; Reid, D. M.; Amidei, A.; Bassiti, A.; Bustamante, M.; Husted, L. B.; Diez-Perez A.; Dobnig H.; Dunning, A. M.; Enjuanes, A.; Fahrleitner-Pammer, A.; Fang, Y.; Karczmarewicz, E.; Kruk, M.; van Leeuwen, J. P.; Mavilia, C.; van Mears, J. B.; Mangion, J.; McGuigan, F. E.; Pols, H. A.; Renner, W.; Rivadeneira, F.; van Schoor, N. M.; Scollen, S.; Sherlock, R. E. and Ioannidis, J. P. (2006a) The association between common vitamin D receptor gene variations and osteoporosis: a participant-level meta-analysis. Ann. Intern. Med. 145, 255-264.
107. Uitterlinden, A. G.; van Meurs, J. B.; Rivadeneira, F. and Pols, H. A. (2006o) Identifying genetic risk factors for osteoporosis. J. Musculoskelet. Neuronal Interact. 6, 16-26.
108. van Meurs, J. B.; Rivadeneira, F.; Jhamai, M.; Hugens, W.; Hofman, A.; van Leeuwen, J. P.; Pols, H. A. and Uitterlinden, A. G. (2006) Common genetic variation of the low-density lipoprotein receptor-related protein 5 and 6 genes determines fracture risk in elderly white men. J. Bone Miner. Res. 21, 141-150.
109. Watts, N. B.; Geusens, P.; Barton, I. P. and Felsenberg, D. (2005) Relationship between changes in BMD and nonvertebral fracture incidence associated with risedronate: reduction in risk of nonvertebral fracture is not related to change in BMD. J. Bone Miner. Res. 20, 2097-2104.
110. Yahata, T.; Quan, J.; Tamura, N.; Nagata, H.; Kurabayashi, T. and Tanaka, K. (2005) Association between single nucleotide polymorphisms of estrogen receptor alpha gene and efficacy of HRT on bone mineral density in post-menopausal Japanese women. Hum. Reprod. 20, 1860-1866.
111. Yamada, Y.; Harada, A.; Hosoi, T.; Miyauchi, A.; Ikeda, K.; Ohta, H. and Shiraki, M. (2000) Association of transforming growth factor betal genotype with therapeutic response to active vitamin D for post-menopausal osteoporosis. J. Bone Miner. Res. 15, 415-420.
112. Yim, C. H.; Choi, J. T.; Choi, H. A.; Kang, Y. S.; Moon, I. G.; Yoon, H. K.; Han, I. K.; Kang, D. H. and Han, K. O. (2005) Association of estrogen receptor alpha gene microsatellite polymorphism with annual changes in bone mineral density in Korean women with hormone replacement therapy. J. Bone Miner. Metab. 23, 395-400.
113. Young, R.; Wu, F.; Van de, W. N.; Ames, R.; Gamble, G. and Reid, I. R. (2003) Calcium sensing receptor gene A986S polymorphism and responsiveness to calcium supplementation in postmenopausal women. J. Clin. Endocrinol. Metab. 88, 697-700.
114. Zhang, Z. L.; He, J. W.; Huang, Q. R.; Qin, Y. J.; Hu, Y. Q.; Li, M.; Zhang, H.; Liu, Y. J. and Hu, W. W. (2006) [Relationship between the polymorphism of start codon and CDX2 site in vitamin D receptor gene and the effect of calcium supplementation on bone mineral density of postmenopausal women]. Zhonghua Yi Aue Yi Chuan Xue Za Zhi 23, 397-401.